Ubushakashatsi bw'Iterambere bwasohotse mu gitabo cy'amaraso: Uburyo bwo kuvura CD7 CAR-T bushingiye kuri Nanobody ku ndwara ya kanseri y'imitsi ikabije ya Myeloid Leukemia
Itsinda ry’abaganga rya Lu Daopei ryateye intambwe itangaje mu bijyanye n’amaraso. Bayobowe na Dr. Lu Peihua, ubushakashatsi bwabo bw’ibanze, "Antijeni ya CD7-Targeted Chimeric ishingiye kuri Nanobody ishingiye ku buryo bw'umwimerere Agasanduku ka T k'umukiriya "Ubuvuzi bwo kuvura kanseri y'amaraso ya Myeloid ikabije", iherutse gusohoka mu kinyamakuru kizwi ku rwego mpuzamahanga Amaraso (Ingaruka: 21). Ubu bushakashatsi bwerekana uburyo bushya bwo kuvura kanseri y’imitsi ikabije (AML), bugaragaza ubushobozi n’umutekano bidasanzwe mu kwica ikibyimba mu gihe butanga icyizere gishya ku barwayi ba AML basubiye inyuma cyangwa badafite ubushobozi bwo kuvura (R/R).
Uburyo bushya bwo guhanga udushya
Ubushakashatsi bwatangije ikoreshwa ry’uturemangingo twa CD7 CAR-T dushingiye kuri nanobody mu buvuzi bwa AML. Ubusanzwe uburyo bwo kuvura bwa CAR-T bukoresha ibice by’uruhererekane rumwe (scFv) bikomoka kuri antibodies za monoclonal (mAbs). Ubu bushakashatsi bwifashishije nanobodies—antibodies za single-domain zikomoka kuri antibodies za camelid heavy-chain. Nanobodies, bitewe n’ingano yazo nto (15kDa ugereranije na 150kDa human IgG) no kugabanuka k’ubudahangarwa bw’umubiri, zitanga umwihariko mwiza wa antigen no gufatana mu gihe zigabanya ingaruka mbi.
NS7CAR-T ishingiye kuri nanobody yagaragaje ko irwanya ikibyimba ryarushijeho kuba ryiza ndetse n'umutekano waryo mu igeragezwa rya mbere ndetse no mu isuzuma rya nyuma. Ibisubizo bya mbere byagaragaje ko ingirabuzimafatizo ziyongera cyane kandi zirwanya ikibyimba ugereranije n'uturemangingo twa CAR-T dushingiye kuri scFv. Byongeye kandi, mu igerageza rya mbere rya nyuma, ubuvuzi bwageze ku gipimo cya 70% cy'uko abarwayi 10 banduye CD7 banduye AML, aho 60% bageze ku kigero gito cy'indwara zisigara (MRD).
Ingaruka z'ubuvuzi
Igerageza ryigaga abarwayi bafite ibyago byinshi byo kwandura, harimo n’ababanje guterwa selile z’amaraso (allo-HSCT) cyangwa imiti myinshi. Nubwo hari izi mbogamizi, ubuvuzi bwa NS7CAR-T bushingiye kuri nanobody bwageze ku musaruro mwiza hamwe n’ingaruka mbi zishobora gukemuka, harimo n’indwara yo gusohora cytokine (CRS) mu 80% by’abitabiriye. Nta ndwara y’uburozi bw’ubwonko yagaragaye.
Amabwiriza y'ejo hazaza
Ubu bushakashatsi bugaragaza ko hakenewe igeragezwa rinini kugira ngo harebwe neza imikorere n'umutekano w'ubuvuzi bwa CD7 CAR-T bushingiye kuri nanobody mu kuvura AML. Bunagaragaza imbogamizi nko gutakaza antigen ya CD7, bikomeje kuba imbogamizi ikomeye ku bantu basubiranyemo. Gukemura ibi bibazo bizaba ingenzi mu kunoza uburyo bwo kuvura hakoreshejwe uburyo bwagutse bwo kuvura.
Icyerekezo Gishya cyo Kuvura AML
AML, kanseri y’amaraso igoye cyane kandi itandukanye, imaze igihe kinini iteza ibibazo mu kugera ku ndunduro irambye no kunoza umubare w’abarokoka muri rusange. Ubu buryo bushya bwashyizweho n’itsinda ry’abaganga rya Lu Daopei ntibutanga gusa uburyo bushya bwo kuvura abarwayi ahubwo bunashimangira ubuhanga bwabo mu bushakashatsi ku isi mu bijyanye n’amaraso.
Iyi ntambwe ikomeye ni ikimenyetso cy'ubwitange bw'ikipe mu guhuza ubushakashatsi bugezweho n'imikorere y'ubuvuzi. Mu gihe itsinda rikomeje gushakisha uburyo bushya bwo kuvura, akazi kabo kazana icyizere gishya ku barwayi bo ku isi yose kandi gatanga inzira yo gutera imbere mu bijyanye n'amaraso.